Cyclosporine (CSA) is a new immunosuppressant which has selectivity for the immune system and is without systemic side effects at therapeutic doses. In contrast to the cytotoxic class of immunosuppressants, no myelotoxic, teratogenic, mutagenic, or carcinogenic effects were observed. Nevertheless, overdosage may lead to renal dysfunction, which occurs mainly in rats, and often complicates its clinical use. The expcrimental data also showed that significant nephrotoxicity was only caused under specific conditions at therapeutic doses. These conditions included ischemia, hcminephrectomy, concomitant administration of nephrotoxic drugs, and/or genetic prcdisposition. Thus, concomitant renal damage is a prerequisite in order to obtain overt nephrotoxicity at therapeutic CSA doses. Since these conditions cannot be avoided in patients, nephrotoxicity often occurs at therapeutic doses in man (45). The rat might be a suitable expenmental model of CSA nephropathy displaying similar morphologic and functional changes as observed in man. This model also allows further investigations on the pathogenic mechanisms which are elusive at the present time.
INTRODUCTION
Nephrotoxicity is a relatively common problem in patients immunosuppressed with cyclosporine (CSA). The incidence is in the range of thirty percent. Nephrotoxicity is characterized by rapid serum creatinine increases and reduction of glomerular filtration rate (GFR) and may be associated with mild arterial hypertension (5, 31, 32, 43, 44) . Histological changes in renal biopsies include tubular, arterial and glomerular changes as well as interstitial fibrosis (22, 26, 27, 38) .
Because of the complex clinical setting in which CSA is prescribed, efforts have been made to study pathophysiology of nephrotoxicity in animal models (6, 15, 35, 49) . Pharmacological and toxicological data will be shortly reviewed, an animal model will be proposed, and experimental findings will be discussed in the context of a recent workshop on this topic (46).
REVIEW OF PIiARhfACOLOGY AND TOXICOLOGY
Inir?iutiopkarr,iacology of CSA. CSA selectively modulates defined subpopulations of immunocompetent cells and has no adverse effect on hemopoiesis. The it1 vifro and in vivo reversibility of its immunosuppressive activity indicates that it is not due to a lymphocytotoxic action. Present knowledge indicates that CSA inhibits specifically IL-2 synthesis at the level of nuclear transcription of the gene product (3). This effect may explain the suppression of in vivo immune responses such as delayed-type hypersensitivity, organ graft acceptance, and humoral T-dependent immune responses.
Toxicology. Since CSA belongs to a completely new class of immunosuppressants, an extensive toxicological evaluation was necessary prior to clinical trials. A short summary of the results of acute, subacute, chronic toxicity, reproduction, and carcinogenicity studies will be given as these have been published (34).
Acufe Toxicity. In studies performed in mice, rats and rabbits, LD50 values after single intravenous injection were 107,25, and 10 mg/kg. Following oral administration, the values were 2,300, 1,500, and >1,000 mg/kg in mice, rats and rabbits. No target organ toxicity was apparent.
Subacute toxicity was evaluated in monkeys, dogs, and rats (Table I) . The major findings were nephrotoxicity, hepatotoxicity, atrophy of lymphoid tissue, atrophic gingivitis, and depression of erythropoiesis in rats given high CSA doses. By contrast, oral CSA did not cause any toxicity in monkeys and dogs. Intravenous administration, however, caused renal and hepatic changes in monkeys.
Chroriic toxicity arid carciriogeriicity studies were performed in dogs, rats, and mice (Table I) Reproductive Toxicity. The effects of CSA on reproduction were evaluated in rabbits and rats. These studies revealed embryolethality at doses toxic to the mothers, but no teratogenic effects were observed. Peri-and postnatal development, fertility, and reproductive performance were not affected at doses which were non-toxic for the parental animals.
Miitagetticity. CSA was assayed in various test systems and all tests were negative (25).
In conclusion, CSA was well tolerated by various animal species and was without systemic side effects at therapeutic doses. However, overdosage caused renal and to a lesser extent hepatic toxicity, mainly in rats.
ANIhfAL MODEL OF CSA NEPHROTOXICITY
Present investigations aimed at an experimental model, reflecting clinical CSA nephrotoxicity, for example, GFR reduction, arteriolopathy, and arterial hypertension. Based on the toxicological data the rat was chosen for further investigation.
Serisitivity of Various Straitis of Rats. CSA was tested orally at 50 mg/kg/day for 14 days in the following strains: Spontaneously hypertensive (SH), Sprague-Dawley (SD), Wistar (WSA), Fischer (FIS), and Lcwis (LEW) rats. In all strains a reduction of GFR as well as renal tubular changes were observed (Table 11 ). Based on the results of this experiment, the following rank ordcr for scnsitivity to CSA effects in these strains can be proposed: SH > FIS = LEW > WSA > SD.
Pilot Study it1 Spotitaneoiisly Hypertetuive Rats.
A lower dose of 20 mg/kg/day was given to male and female SH rats orally for 4 weeks. The dose of 20 mg/kg is about twice the therapeutic dose used in renal transplantation. The results of this study included decreased body weight gain, increased serum creatinine and BUN, decreased creatinine clearance, accelerated development of AP, increased plasma renin activity (PRA), and no significant effect on blood pressure (Table 111) . Male rats were more sensitive than female rats and developed both functional and morphologic changes due to CSA. Morpliologic Changes. a) Tiibiilar changes. CSA induced characteristic lesions in the proximal tubule (S, and S3 segment). The tubular lesions consisted of irregular, small to large cytoplasmic vacuolization, inclusion bodies and microcalcification of the dystrophic type as shown in Fig. 1 . The inclusion bodies reached the size ofthe cell nucleus and stained red with the chromotrope aniline blue stain (36). Electron microscopy revealed enlarged lysosomes containing mainly degradated mitochondria corresponding to the inclusion bodies observed with light microscopy. Myelin bodies and extensive tubular necrosis, which commonly occur in aminoglycoside nephrotoxicity, were never present (33). These tubular changes were seen by light microscopy mainly at high doses and are considered indicators of CSA overdosage. b) Arferiolar clianges. Histologically typical arteriolar changes were observed, which were more distinct in older, CSA treated SH rats. At low CSA doses a more exudative form with fibrinoid media necrosis (Fig. 2) was present, whereas at higher doses or after prolonged CSA administration a more proliferative form of arteriolopathy with obliteration of the vessel lumen predominated (Fig. 2) .
Tittle Dependence and Rewsibility. The effect of a high dose CSA (1 00 mg/kg/day) was studied in male SH rats (Table IV) . Tubular alterations were already seen after 3 days of drug administration; AP was only detected after 10 days of treatment and was not reversible after 10 days recovery period.
Functional Changes. Male SH rats were given various doses of CSA, from 0 to 100 mg/kg/day for 4 weeks. The main findings were: There was a dosedependent decrease in body weight gain at levels higher than 20 mg/kg/day and decreased water and food intake at 50 mg/kg/day or higher. At 100 mg/ kg, central nervous toxicity became apparent by hyperreactivity, convulsions and death in fifty percent of the animals.
Serum chemistry showed dose-dependent BUN and creatinine increases (Table V) , hypcrglycemia, hypoalbuminemia, and distinct changes in serum electrolytes, including decreased Na+, elevated K+, and lower Caz+. Urinalysis revealed dose-dependent aciduria, slightly increased volume with calciuria, sodium retention, and decreased osmolality.
GFR, as measured by the creatinine or inulin clearances, was dose-dependently decreased (data not shown).
Effects on blood pressure (BP) and heart rate (HR) are shown in Fig. 3 . Low doses of CSA caused hypertension and tachycardia, whereas at high doses, greater than 50 mg/kg/day, the BP and HR werc normalized or even lower than controls.
CSA trough levels in blood were in the pg/ml range and correlated fairly well with the administered doses. The effects of CSA on PRA paralleled that on BP. Thus, at the lower doses PRA was increased, whereas at high doses, PRA was in the control range or even decreased.
PHARMACOKINETICS
In order to validate an experimental system, pharmacokinetic parameters such as absorption, distribution, metabolism, and excretion of a compound have to be compared with data obtained in man. Detection of CSA in blood or serum was made possible by the development of a radioimmunoassay (RIA) and a liquid chromatographic technique (HPLC) (12,29) . Since the antibody used in the RIA crossreacted with metabolites, this method overestimated levels of the parent molecule by twofold. 
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FIG. 2.-Arteriolar lesions in CSA treated SH rats: exudative type with media necrosis (top) and proliferative type (bottom) with obliteration of the vessel lumen; Chromotrope aniline blue stain. x 350.
sorbed from the gastrointestinal tract in rats, reaching peak serum levels at 4-6 hours as detected by RIA. Radiolabeled CSA accumulated in liver, kidney, fat, lymphoid tissue and skin, whereas almost no radioactivity was detected in brain (29) . CSA is metabolized in the liver and includes hydroxylation and N-demethylation resulting in more than 10 metabolites, all preserving the peptide ring structure (24).
Cunningham et a1 (7) showed that induction of hepatic cytochrome 450 in rats accelerated metabolism and reduced toxicity. These results indicate that the parent molecule, rather than the metabolite, is responsible for nephrotoxicity. Elimination occurs via the bile into the feces, and only about 5% is eliminated by the urine.
Tiibular Acciitiitilalion of CSA. Von Willebrand and Hayry claimed to detect material in human tubular cells which reacted with the antibody used in the RIA (52). It was assumed that this finding meant CSA accumulated in tubular cells, indicating CSA nephrotoxicity (53) . Using identical techniques, we were unable to demonstrate CSA. reactive material in rat or in human renal tissue.
In conclusion, CSA is readily absorbed from the gastrointestinal tract, extensively metabolized in the liver, and eliminated via the bile. Toxicity is most likely due to the parent molecule. Interferences with hepatic metabolism may change the bioavailability of CSA, resulting in altered pharmacokinetics. A comparison of rat findings with human data indicates that pharmacokinetic parameters correlate fairly well between the two species (4, 24) and that the metabolic differences are quantitative rather than qualitative.
FACTORS AFFECTING SUSCEPTIDILITY TO EXPERIMENTAL CSA NEPHROTOXICITY Age. Both functional and morphological changes are more easily induced in older rats, whereas young rats are more resistant to CSA nephrotoxicity.
Sex. Based on the toxicological data and experimental studies, male rats are more susceptjble to CSA nephrotoxicity than females.
Zschentia. Ischemia is an important factor in clinical situations; thus, the impact of experimental ischemia was tested. Thiel et a1 (45) reported t h h warm ischemia in rats aggravated CSA nephrotoxicity. Similar data were obtained by other investigators in dogs, but not in rabbits (9, 10).
Heniinephrectorny. Based on the experimental data another factor which may increase nephrotoxicity of CSA is heminephrectomy (17, 37) . Also, it was concluded that renal adaptation after heminephrectomy is impaired by CSA treatment.
Nonsteroidal Antiiriflaniniatory Drugs. Inhibition of the prostaglandin synthesis with the cyclooxygenase inhibitor indomethacin enhanced CSA toxicity (39). These results give circumstantial evidence that regulatory mechanisms controlled by the prostaglandin system may be important (14) .
Dehydration. Volume depletion may be important as indicated by a decreased urinary volume and water intake in the late stage of CSA intoxication in rats. Thus, administration of diuretics for a prolonged period might enhance toxicity. Furosemide was shown to increase CSA toxicity in rats due to Na+ depletion and dehydration (5 1). NaCI Load. Administration of 0.99'0 NaCl as drinking solution (ad libittint) to CSA treated rats caused deterioration of renal parameters compared with tap water control rats (41) .
Chemotherapeutics. Administration of antibiotics with a nephrotoxic potential may be damaging to CSA treated rats. Thus, concomitant treatment with gentamicin and CSA at high doses clearly had a detrimental effect on renal function in rats (SO). interactions are known: The concomitant administration of the antifungal drug ketoconazole increased CSA nephrotoxicity by means of decreased drug elimination (1 6, 48). Conversely, phenytoin and rifampicin increased CSA elimination necessitating higher CSA doses (8, 21) . Prednisone metabolism may be increased in CSA treated patients (30), and trimethoprim and cotrimoxazole, with no nephrotoxic effects when given alone, may enhance CSA nephrotoxicity (47).
Drug Interactions. Clinically, the following drug

PREVENTION OF CSA NEPHROTOX~CITY
Various strategies for reducing CSA nephrotoxicity were investigated, and a few of these experiments are summarized below: a) Probeiiecid. Renal tubular accumulation of various antibiotics was reported to be reduced by probenecid, a known blocker of the organic anion transport system. Thus, WSA rats treated with'high CSA doses were given probenecid concomitantly. Except for a slight decrease in BUN levels, probenecid neither altered the pharmacokinetic profile not nephrotoxicity (54). b) Prostaglairdirt (PGE,). Administration of dimethyl-PGE, decreased CSA toxicity in Wistar-Furth rats (23) . These findings were not unexpected in view of the effects of prostaglandin synthesis inhibition, by NSAIDs. However, preliminary results from our own experiments in SH rats indicate that PGE, might diminish CSA bioavailability (46). c) Glircose. Administration of 5% glucose as drinking solution to normotensive and hypertensive rats diminished general and renal toxicity. This effect might be due to rehydration and increased caloric intake. Gerkens et al(l8) showed that a NaCl drinking solution in Na+-depleted normotensive rats decreased nephrotoxicity. This effect might also be due to rehydration. d) Hydergine. Daily adminstration of hydergine (0.3 mg/kg subcutaneously), which has antihypertensive properties, reduced general and renal side effects of CSA. Based on the preliminary results, the beneficial effects were independent of blood pressure reduction (42).
COMPARISON WITH GENTAMICIN
NEPHROTOXICITY The nephrotoxic potential of CSA was compared with that of gentamicin (33) in rats, as shown in Table VI . Whereas gentamicin induced acute renal failure with distinct serum BUN and creatinine increases, CSA had only minor effects on these parameters. Both agents affected proximal tubular cell integrity; CSA caused vacuolization whereas gentamicin caused extensive tubular necrosis with myelin bodies. Gentamicin, as a hydrophilic compound, is filtered in an unchanged form and partially concentrated in the epithelium of the proximal tubule. The lipophilic CSA undergoes extensive hepatic metabolism, has a low renal clearance, and tubular accumulation was not demonstrated.
FACTS AND SPECUIATIONS ON
CSA NEPHROTOXICITY A recent workshop on experimental CSA nephrotoxicity gave the opportunity to discuss findings of various experimental models and to speculate on 80 RYFFEL AND MIHATSCH TOXICOLOGIC PATHOLOGY the factors causing nephrotoxicity (46) . The relevant findings are summarized below. hforphologic Changes. A general agreement was reached on proximal tubular changes which include inclusion bodies, vacuolization and calcification, occasional mitotic figures, and loss of microvilli. No significant changes were observed in other segments of the nephron including the glomeruli. Arteriolopathy (AP) was only observed in SH rats, and vascular disease was not induced by CSA in any normotensive rat strain. Furthermore, five-sixths nephrectomy and Goldblatt rats showed no evidence of vascular disease. A syndrome of vascular thrombosis was observed in rabbits and rats with experimental serum sickness and concomitant CSA administration (28) . Increased size and'granularity of the juxtaglomerular apparatus was reported. The major limitation of all the experimental models is the fact that these models describe acute nephrotoxicity. No experimental system reflecting chronic toxicity with fibrosis as observed in man, was presented. The only exception is probably the SH rats, where fibrosis may be found after prolonged treatment.
Ainctional Changes. Reduction of GFR and RPF (filtration fraction remaining constant) after single intravenous or repeated oral administration of CSA was reported in various strains of rats and in dogs. Determination of GFR may be influenced by prerenal factors, since CSA causes reduction of body weight gain or even weight loss. Thus, it was agreed that all experiments should be performed under strict pair-feeding conditions in order to exclude prerenal factors. Paller was able to abolish a GFR reduction by a-blockade or chemical denervation (46) . Sodium reabsorption as demonstrated by the lithium clearance was increased in the proximal tubule (1 1). The morphologic tubular alterations, however, would predict tubular dysfunction.
Micropuncture experiments indicated a decreased proximal sodium reabsorption (1 9). Thus, the effects on sodium transport, as well as on the diluting segment ofHenle, have to bc studied in more detail.
Decreased K+ and H+ secretion in the voltage dependent segment of the collecting duct was presented, which might explain the clinically observed metabolic hyperkalemic acidosis (1).
